GlassScriptPhysician profile
Heather Murray
NPI 1952956419
$6,013.15
in general payments reported to CMS, 2019-2025
23 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $420 · 2022: $1,139 · 2023: $1,717 · 2024: $1,306 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,160 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,160.34 |
| Education | $294.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,143.90 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $721.12 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $612.28 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $437.31 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $381.36 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $376.18 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $353.70 | 2021-2025 | Winlevi |
| Lilly USA, LLC | $343.32 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $289.82 | 2023-2025 | Tremfya |
| Pfizer INC. | $287.08 | 2022-2025 | |
| Incyte Corporation | $226.17 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $121.94 | 2023-2025 | Sotyktu |
| Amgen INC. | $118.84 | 2024-2025 | Otezla |
| Galderma Laboratories, L.P. | $104.93 | 2021-2025 | Nemluvio, Dysport |
| Merz North America, INC. | $85.52 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $85.33 | 2022-2023 | Adbry |
| Organogenesis INC. | $83.22 | 2024-2025 | Puraply Am, Apligraf |
| Biofrontera INC. | $77.68 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $47.11 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.31 | 2024-2025 | Cabtreo |
| Merz Pharmaceuticals, LLC | $27.80 | 2021 | |
| Vyne Pharmaceuticals INC. | $22.97 | 2021 | |
| Botanix Sb INC | $19.26 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.